Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
The management of patients with myelodysplastic syndrome (MDS) refractory to hypomethylating agents (HMAs) remains a challenge with few reliably effective treatments. Preclinical studies have shown that the inhibition of the nuclear export protein XPO1 causes nuclear accumulation of p53 and disrupti...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2024-12-01
|
| 叢編: | Frontiers in Oncology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1477697/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|